View on Pubmed.gov 34039486 | View on doi.org 10.1016/j.jhep....
Sarcopenia and frailty in decompensated cirrhosis.
- Division of Gastroenterology & Liver Unit, University of Alberta Hospital, Canada. Electronic address: ptandon@ualberta.ca.
- Division of Gastroenterology & Liver Unit, University of Alberta Hospital, Canada.
- Divisions of Gastroenterology and Hepatology, University of California, San Francisco, San Francisco, CA, USA.
- Division of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, OH, USA.
- Department of Clinical Medicine, Gastroenterology, Sapienza University of Rome, Italy. Electronic address: manuela.merli@uniroma1.it.
Abstract
In patients with decompensated cirrhosis, sarcopenia and frailty are prevalent. Although several definitions exist for these terms, in the field of hepatology, sarcopenia has commonly been defined as loss of muscle mass, and frailty has been broadly defined as the phenotypic manifestation of the loss of muscle function. Prompt recognition and accurate assessment of these conditions are critical as they are both strongly associated with morbidity, mortality, poor quality of life and worse post-liver transplant outcomes in patients with cirrhosis. In this review, we describe the complex pathophysiology that underlies the clinical phenotypes of sarcopenia and frailty, their association with decompensation, and provide an overview of tools to assess these conditions in patients with cirrhosis. When available, we highlight data focusing on patients with acutely decompensated cirrhosis, such as inpatients, as this is an area of unmet clinical need. Finally, we discuss management strategies to reverse and/or prevent the development of sarcopenia and frailty, which include adequate nutritional intake of calories and protein, as well as regular exercise of at least moderate intensity, with a mix of aerobic and resistance training. Key knowledge gaps in our understanding of sarcopenia and frailty in decompensated cirrhosis remain, including best methods to measure muscle mass and function in the inpatient setting, racial/ethnic variation in the development and presentation of sarcopenia and frailty, and optimal clinical metrics to assess response to therapeutic interventions that translate into a reduction in adverse outcomes associated with these conditions.
References
Nature. 2010 Mar 25;464(7288):529-35
J Mol Med (Berl). 2008 Oct;86(10):1113-26
Hepatology. 1996 May;23(5):1041-6
Clin Gastroenterol Hepatol. 2016 Oct;14(10):1473-1480.e3
Cited by 261 citations (total)
Randomized Controlled Trial Journal Article
A nomogram based on psoas muscle index predicting long-term cirrhosis incidence in non-cirrhotic patients with HBV-related acute‑on‑chronic liver failure.
Electronic publication date December 4, 2023
Jie Bai [...] Yongguo Li et al.
There is a lack of scoring system to predict the occurrence of cirrhosis in individuals with acute-on-chronic liver failure (ACLF)...
Journal Article Review
Current Medical Treatment for Alcohol-Associated Liver Disease.
Electronic publication date September 27, 2022
Gustavo Ayares [...] Juan P Arab et al.
Alcohol-associated liver disease is one of the main causes of chronic liver disease. It comprises a clinical-histologic spectrum of presentations,...
Conflict of interest statement
Conflict of interest The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.
MeSH
- •
- •
- •
Specialties
- •
- •
- •
- •
- •
- •
Copyright
Copyright © 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.